TiumBio Co Ltd
TiumBio Co Ltd is a biotechnology company engaged in pharmaceuticals and medical research, primarily generating revenue through product sales and R&D activities.
Business. TiumBio Co Ltd (321550.KQ) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
TiumBio Co Ltd (321550.KQ) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
TiumBio operates with a capital structure that shows a debt-to-equity ratio of 1.11, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 1.11, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's cash and equivalents amount to 10,695,875,750 KRW, which is significantly lower than its long-term debt of 45,245,022,630 KRW, resulting in a negative net cash position.
Profitability metrics for TiumBio are concerning, with a return on equity (ROE) of -0.4255 and a return on assets (ROA) of -0.1762, both well below the industry norms. The company reported a net loss of 17,360,323,230 KRW and an operating loss of 17,265,169,160 KRW, indicating significant operational challenges. The gross profit margin stands at 41.04%, which is relatively high but insufficient to offset the company's operating expenses.
Geographically and segment-wise, TiumBio's revenue concentration is not explicitly detailed in the available data. However, the company's financial snapshot does not provide a breakdown of revenue by geographic region or business segment, making it difficult to assess the diversification of its revenue streams.
The company's growth trajectory is currently negative, with a net loss and declining operating cash flow. The outlook for the current fiscal year does not indicate a reversal of this trend, and the company is expected to continue facing financial pressures. The operating cash flow of -15,302,839,870 KRW and free cash flow of -15,634,731,590 KRW highlight the company's inability to generate positive cash from operations.
Risk factors for TiumBio include a medium liquidity risk, primarily due to the negative net cash position after accounting for total debt. The company's dilution risk is assessed as low, but the potential for dilution remains a concern given the negative net income and the need for additional capital. The company's valuation adjustments and risk assessments suggest that the market is pricing in these risks, as reflected in the price-to-book ratio of 5.38.
Recent events and filings do not provide specific details on new product launches or strategic partnerships. However, the company's financial performance and risk profile suggest that it is under pressure to improve its operational efficiency and secure additional funding to sustain its operations.
- TiumBio has a negative net income and operating income, indicating significant financial distress.
- The company's liquidity position is moderate, with a current ratio of 1.11, but it has a negative net cash position.
- TiumBio's profitability metrics are poor, with a return on equity of -0.4255 and a return on assets of -0.1762.
- The company's growth trajectory is negative, with declining operating cash flow and free cash flow.
- TiumBio faces medium liquidity risk and low dilution risk, but the potential for dilution remains a concern.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- TiumBio Co Ltd Market data — financials · 2026-05-26